Can GLP-1 Medications Help Lower Cancer Risk?

In a recent conversation with The Educated Patient, Dejana Braithwaite, Ph.D., M.Sc., associate director for Cancer Prevention and Control at the University of Florida Health Cancer Institute, explored an important and evolving question: How might GLP-1 receptor agonists fit into the broader picture of cancer prevention?

Braithwaite emphasized that cancer prevention is not about a single action; it’s about improving overall health over time. One key factor is excess body fat, or adiposity, which can influence cancer risk through multiple biological pathways. These include chronic inflammation, disruptions in insulin and growth signaling, and hormonal changes that may, over years, create an environment where cancer is more likely to develop. Because GLP-1 medications can support weight loss and improve metabolic health, researchers are increasingly asking whether they might also help reduce some of these underlying cancer risks.

What We Know — and What We Don’t

While the idea is promising, Braithwaite was clear that the science is still developing. Some early findings suggest potential concerns, including gastrointestinal side effects such as pancreatitis and possible impacts on body composition. Importantly, there is not yet enough evidence to determine whether these medications directly reduce cancer risk or improve outcomes for patients already diagnosed with cancer.

She also highlighted that these therapies are not one-size-fits-all. Certain populations, such as older adults or those with frailty, may face additional risks, underscoring the need for personalized care. Ongoing research will be essential to better understand who may benefit most and how to safely integrate these medications into prevention strategies.

A Tool, Not a Replacement

For patients, the key takeaway is balance. GLP-1 medications may become one part of the cancer prevention conversation, particularly for individuals with obesity or metabolic risk factors. However, they should never be viewed as a guarantee against cancer or a substitute for proven prevention strategies.

Braithwaite reinforced that the foundations of cancer prevention remain critical:

• Avoiding tobacco
• Staying up to date on recommended cancer screenings
• Maintaining regular physical activity
• Following a healthy diet
• Managing weight and limiting alcohol intake
• Controlling chronic conditions

Ultimately, GLP-1 therapies represent a potential addition to a much larger prevention framework, not a stand-alone solution. Their benefits are most meaningful when paired with ongoing medical care and healthy lifestyle changes. As research continues, these medications may help refine how we approach cancer risk, but for now, a comprehensive, individualized strategy remains the cornerstone of prevention.